Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
Saved in:
| Title: | Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer. |
|---|---|
| Authors: | Perimbeti S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Medical Oncology, Penn State Cancer Institute, Hershey, PA, USA., Jamroze A; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Gopalakrishnan D; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Oncology, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE., Jain R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Division of Hematology and Oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY, USA., Jiang C; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Holleran JL; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Bies R; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York at Buffalo, Buffalo, NY, USA.; Institute for Computational and Data Sciences, University at Buffalo, State University of New York at Buffalo, Buffalo, NY, USA., Quinn D; Abbvie, South San Francisco, CA, USA., Attwood K; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Liu X; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Green K; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Kirk JS; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA.; Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA., Tang DG; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dean.Tang@Roswellpark.org.; Experimental Therapeutics Graduate Program, University at Buffalo and Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dean.Tang@Roswellpark.org., Chatta G; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Gurkamal.Chatta@Roswellpark.org. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 Nov 29; Vol. 95 (1), pp. 115. Date of Electronic Publication: 2025 Nov 29. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
